STUDY OF TAMOXIFEN AND EXEMESTANE MORE GNRH ANALOGUE AS ADJUVANT THERAPY FOR PREMENOPAUSIC WOMEN WITH BREAST CANCER WITH ENDOCRINE RESPONSE
Not Applicable
Completed
- Conditions
- -C50 Malignant neoplasm of breastMalignant neoplasm of breastC50
- Registration Number
- PER-069-03
- Lead Sponsor
- INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Premenopausal women [estradiol (E2) in premenopausal ranges (according to institutional parameters) after surgery] Patients should be randomized within 12 weeks of definitive surgery.
Exclusion Criteria
not contemplated
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method